Reuters logo
5 months ago
BRIEF-CSL says FDA accepts CSL Behring's biologics license application supplement for using Privigen to treat CIDP
February 14, 2017 / 2:47 PM / 5 months ago

BRIEF-CSL says FDA accepts CSL Behring's biologics license application supplement for using Privigen to treat CIDP

1 Min Read

Feb 14 (Reuters) - CSL Ltd

* FDA accepts CSL Behring's biologics license application supplement for using privigen® to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare neurological condition Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below